J 2024

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

MUSTO, Pellegrino; Jon SALMANTON-GARCIA; Nicola SGHERZA; Rui BERGANTIM; Francesca FARINA et al.

Základní údaje

Originální název

Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

Autoři

MUSTO, Pellegrino; Jon SALMANTON-GARCIA; Nicola SGHERZA; Rui BERGANTIM; Francesca FARINA; Andreas GLENTHOJ; Cengiz Seval GULDANE; Barbora WEINBERGEROVÁ; Valentina BONUOMO; Yavuz M BILGIN; van Doesum JAAP; Ozren JAKSIC; Benjamin VISEK; Iker FALCES-ROMERO; Monia MARCHETTI; Julio DAVILA-VALLS; Sonia MARTIN-PEREZ; Marcio NUCCI; Alberto LOPEZ-GARCIA; Federico ITRI; Caterina BUQUICCHIO; Luisa VERGA; Klara PIUKOVICS; Milan NAVRATIL; Graham P COLLINS; Moraima JIMENEZ; Nicola S FRACCHIOLLA; Jorge LABRADOR; Lucia PREZIOSO; Elena ROSSI; Natasha COLOVIC; Stef MEERS; Austin KULASEKARARAJ; Annarosa CUCCARO; Ola BLENNOW; Toni VALKOVIC; Uluhan SILI; Marie-Pierre LEDOUX; Josip BATINIC; Francesco PASSAMONTI; Marina MACHADO; Rafael F DUARTE; Christian Bjorn POULSEN; Gustavo-Adolfo MENDEZ; Ildefonso ESPIGADO; Fatih DEMIRKAN; Martin CERNAN; Chiara CATTANEO; Verena PETZER; Gabriele MAGLIANO; Carolina GARCIA-VIDAL; Shaimaa EL-ASHWAH; Maria GOMES-DA-SILVA; Antonio VENA; Irati ORMAZABAL-VELEZ; van Praet JENS; Michelina DARGENIO; Cristina DE-RAMON; Del Principe Maria ILARIA; Joyce MARQUES-DE-ALMEIDA; Dominik WOLF; Tomas SZOTKOWSKI; Ales OBR; Goekce Melis COLAK; Anna NORDLANDER; Macarena IZUZQUIZA; Alba CABIRTA; Giovanni Paolo Maria ZAMBROTTA; Raul CORDOBA; Pavel ZAK; Emanuele AMMATUNA; Jiri MAYER; Osman ILHAN; Ramon GARCIA-SANZ; Martina QUATTRONE; Elena ARELLANO; Raquel NUNES-RODRIGUES; Ziad EMARAH; Tommaso Francesco AIELLO; Michaela HANAKOVA; Zdenek RACIL; Martina BAVASTRO; Alessandro LIMONGELLI; Laman RAHIMLI; Francesco MARCHESI; Oliver A CORNELY a Livio PAGANO

Vydání

Hematological Oncology, Hoboken, WILEY-BLACKWELL, 2024, 0278-0232

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 3.900

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/24:00135446

Organizační jednotka

Lékařská fakulta

EID Scopus

Klíčová slova anglicky

COVID-19; hematological malignancy; multiple myeloma; SARS-CoV-2

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 2. 2024 08:27, Mgr. Tereza Miškechová

Anotace

V originále

Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological and therapeutic scenarios suggest that there has been an improvement in severity and survival of COVID-19 during the different waves of the pandemic in the general population, but this has not been investigated yet in MM patients. Here we analyzed a large cohort of 1221 patients with MM and confirmed SARS-CoV-2 infection observed between February 2020, and August 2022, in the EPICOVIDEHA registry from 132 centers around the world. Median follow-up was 52 days for the entire cohort and 83 days for survivors. Three-hundred and three patients died (24%) and COVID-19 was the primary reason for death of around 89% of them. Overall survival (OS) was significantly higher in vaccinated patients with both stable and active MM versus unvaccinated, while only a trend favoring vaccinated patients was observed in subjects with responsive MM. Vaccinated patients with at least 2 doses showed a better OS than those with one or no vaccine dose. Overall, according to pandemic waves, mortality rate decreased over time from 34% to 10%. In multivariable analysis, age, renal failure, active disease, hospital, and intensive care unit admission, were independently associated with a higher number of deaths, while a neutrophil count above 0.5 x 109/L was found to be protective. This data suggests that MM patients remain at risk of SARS-CoV-2 infection even in the vaccination era, but their clinical outcome, in terms of OS, has progressively improved throughout the different viral phases of the pandemic.